Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma

Cancer

Volumn 110, Issue 1, 2007, Pages 179-185

  Mauz Körholz, Christine ^a   Gorde Grosjean, Stephanie ^b   Hasenclever, Dirk ^c   Shankar, Ananth ^d   Dörffel, Wolfgang ^e   Wallace, W Hamish ^f   Schellong, Günther ^g   Robert, Alain ^h   Körholz, Dieter ^a   Oberlin, Odile ⁱ   Hall, Georgina W ^j   Landman Parker, Judith ^b  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e HELIOS Clinic   (Germany)

^f ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^h CHU PURPAN   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j JOHN RADCLIFFE HOSPITAL   (United Kingdom)

more..

Author keywords

Children; Hodgkin lymphoma; Lymphocyte predominant; Surgery alone

Indexed keywords

ADOLESCENT; ADVANCED CANCER; ARTICLE; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; EARLY CANCER; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HODGKIN DISEASE; HUMANS; LYMPH NODES; LYMPHOCYTES; MALE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34250793304     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22762     Document Type: Article

References (31)

1. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1083.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
3. Bodis S, Kraus MD, Pinkus G, et al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1997;15:3060-3066.
4. Poppema S. Lymphocyte-predominance Hodgkin's disease. Semin Diagn Pathol. 1992;9:257-264.
5. Marafioti T. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997;337:453-458.
6. Brauninger A, Kuppers R, Strickler JG, Wacker HH, Rajewsky K, Hansmann ML. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc Natl Acad Sci USA. 1997;94:9337-9342.
7. Carbone A, Gloghini A, Gaidano G, et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood. 1998;92:2220-2228.
8. Renne C, Martin-Subero JI, Hansmann ML, Siebert R. Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition. J Mol Diagn. 2005;7:352-356.
9. Regula DP Jr, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med. 1988;318:214-219.
10. Borg-Grech A, Radford JA, Crowther D, et al. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1989;7:1303-1309.
11. Franklin J, Tesch H, Hansmann ML, Diehl V Lymphocyte predominant Hodgkin's disease: pathology and clinical implication [review]. Ann Oncol. 1998;9(suppl 5):S39-S44.
12. Pappa VI, Norton AJ, Gupta RK, et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol. 1995;6:559-565.
13. Nogova L, Reineke T, Eich HT, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol. 2005;16:1683-1687.
14. Trudel MA, Krikorian JG, Neiman RS. Lymphocyte predominance Hodgkin's disease. A clinicopathologic reassessment. Cancer. 1987;59:99-106.
15. Nogova L, Reineke T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma-comparison of outcomes. Eur J Haematol. 2005:75(suppl 66):106-110.
16. Gobbi PG, Broglia C, Merli F, et al. Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma. Cancer. 2003;98:2393-2401.
17. Feugier P, Labourye E, Djeridane M, et al. Comparison of initial characteristics and long term outcome of lymphocyte-predominant Hodgkin's lymphoma patients at clinical stage IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high dose irradiation. Blood. 2004;104:2675-2681.
18. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma. Cancer. 2005;104:1221-1229.
19. Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer. 2002;8:377-383.
20. Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002;94:1731-1738.
21. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765-3771.
22. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285-4289.
23. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated:results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003;101:420-424.
24. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer. 1983;51:2293-2300.
25. Hansmann ML, Zwingers T, Boske A, et al. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol. 1984;10:321-330.
26. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte- predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection - a Study of the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:2948-2952.
27. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003;25:684-687.
28. Lavely WC, Delbeke D, Greer JP, et al. FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:307-315.
29. Guay C, Lepine M, Verreault J, et al. Prognostic value of PET using 18F-FDG in Hodgkin's disease for post treatment evaluation. J Nucl Med. 2003;44:1225-1231.
30. Donaldson S, Link MP, Weinstein HJ, et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol. 2007;20:332-337.
31. Sandoval C, Venkateswaran L, Billups C, Slim M, Jayabose S, Hudson MM. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol. 2002;24:269-273.